Multicenter study on the diagnosis of Alzheimer's disease with FDG-PET---SDAF-PET(study on diagnosis of Alzheimer's disease with FDG-PET)

Not Applicable

• Conditions: Alzheimer' s disease, Frontotemporal lobar degeneration

• Registration Number: JPRN-UMIN000016427
• Lead Sponsor: ational Center for Geriatrics and Gerontology

Brief Summary

The diagnostic performance of FDG-PET in the differential diagnosis of AD and FTLD is higher than that of p-tau181 in CSF. In addition, there is no problem with the safety of FDG-PET.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-02-03
• Study Completion: 2019-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 138

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who have a previous history of or are under treatment for alcoholism. 2)Patients who have a previous history of or are under treatment for epilepsy. 3)Patients who have no more than 6 years of education. 4)Patients with diabetes who are currently receiving insulin therapy. 5)Patients who are currently receiving treatment with antidepressants, antipsychotics, or long-term sedative hypnotics (including anxiolytics). 6)Patients who had a diagnosis of major depression or bipolar disorder within the past year, those who have a previous history of schizophrenia, or those who are considered to have difficulty in completing the protocol due to severe manifestation of psychiatric symptoms, such as anxiety or irritation, within the last 3 weeks. 7)Patients with concurrent serious medical conditions (such as malignancy, heart failure, liver impairment, renal impairment, or endocrine disease). 8)Patients with MRI evidence of local lesions, such as cerebral infarcts, which might affect cognitive function.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A difference in sensitivity between FDG-PET scans and p-tau181 in CSF.

Secondary Outcome Measures

Name	Time	Method
1)A difference in accuracy rate between FDG-PET scans and p-tau181 in CSF. 2)A comparison of the diagnostic performance between clinical diagnosis at month 0 in consideration of CSF biomarkers (tau and Abeta42) versus FDG-PET. 3)Inter-group analyses and other evaluations of FDG-PET scans, CSF biomarkers, MRI scans, and neuropsychological tests between patients with AD and FTLD.